{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:41:12Z","timestamp":1784288472337,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"German Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12985-016-0607-2","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T16:21:55Z","timestamp":1472833315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry"],"prefix":"10.1186","volume":"13","author":[{"given":"Lisa","family":"Hen\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Biedenkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Schnierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nrrheum.2012.64","volume":"8","author":"A Suhrbier","year":"2012","unstructured":"Suhrbier A, Jaffar-Bandjee M-C, Gasque P. Arthritogenic alphaviruses--an overview. Nat Rev Rheumatol. 2012;8:420\u20139. doi: 10.1038\/nrrheum.2012.64 .","journal-title":"Nat Rev Rheumatol"},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1586\/erv.12.84","volume":"11","author":"SC Weaver","year":"2012","unstructured":"Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012;11:1087\u2013101. doi: 10.1586\/erv.12.84 .","journal-title":"Expert Rev Vaccines"},{"key":"607_CR3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrmicro2368","volume":"8","author":"O Schwartz","year":"2010","unstructured":"Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol. 2010;8:491\u2013500.","journal-title":"Nat Rev Microbiol"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/512124a","volume":"512","author":"A Bajak","year":"2014","unstructured":"Bajak A. US assesses virus of the Caribbean. Nature. 2014;512:124\u20135. doi: 10.1038\/512124a .","journal-title":"Nature"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jama.2014.9916","volume":"312","author":"BM Kuehn","year":"2014","unstructured":"Kuehn BM. Chikungunya virus transmission found in the United States: US health authorities brace for wider spread. JAMA. 2014;312:776\u20137. doi: 10.1001\/jama.2014.9916 .","journal-title":"JAMA"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","volume":"377","author":"H Feldmann","year":"2011","unstructured":"Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849\u201362. doi: 10.1016\/S0140-6736(10)60667-8 .","journal-title":"Lancet"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcv.2015.01.014","volume":"64","author":"V Rougeron","year":"2015","unstructured":"Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM. Ebola and Marburg haemorrhagic fever. J Clin Virol. 2015;64:111\u20139. doi: 10.1016\/j.jcv.2015.01.014 .","journal-title":"J Clin Virol"},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature09555","volume":"468","author":"JE Voss","year":"2010","unstructured":"Voss JE, Vaney M-C, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature. 2010;468:709\u201312. doi: 10.1038\/nature09555 .","journal-title":"Nature"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fmicb.2012.00034","volume":"3","author":"A Takada","year":"2012","unstructured":"Takada A. Filovirus tropism: cellular molecules for viral entry. Front Microbiol. 2012;3:34. doi: 10.3389\/fmicb.2012.00034 .","journal-title":"Front Microbiol"},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.tim.2015.04.006","volume":"23","author":"LT Jae","year":"2015","unstructured":"Jae LT, Brummelkamp TR. Emerging intracellular receptors for hemorrhagic fever viruses. Trends Microbiol. 2015;23:392\u2013400. doi: 10.1016\/j.tim.2015.04.006 .","journal-title":"Trends Microbiol"},{"key":"607_CR11","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.72.4.3155-3160.1998","volume":"72","author":"RJ Wool-Lewis","year":"1998","unstructured":"Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol. 1998;72:3155\u201360.","journal-title":"J Virol"},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jviromet.2014.02.001","volume":"201","author":"C Weber","year":"2014","unstructured":"Weber C, Konig R, Niedrig M, Emmerich P, Schnierle BS. A neutralization assay for chikungunya virus infections in a multiplex format. J Virol Methods. 2014;201:7\u201312. doi: 10.1016\/j.jviromet.2014.02.001 .","journal-title":"J Virol Methods"},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/brv.12034","volume":"88","author":"E Kamhi","year":"2013","unstructured":"Kamhi E, Joo EJ, Dordick JS, Linhardt RJ. Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc. 2013;88:928\u201343. doi: 10.1111\/brv.12034 .","journal-title":"Biol Rev Camb Philos Soc"},{"key":"607_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.1026","volume":"22","author":"J Liu","year":"2002","unstructured":"Liu J, Thorp SC. Cell surface heparan sulfate and its roles in assisting viral infections. Med Res Rev. 2002;22:1\u201325.","journal-title":"Med Res Rev"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1128\/JVI.01621-12","volume":"87","author":"B Salvador","year":"2013","unstructured":"Salvador B, Sexton NR, Carrion Jr R, Nunneley J, Patterson JL, Steffen I, et al. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol. 2013;87:3295\u2013304. doi: 10.1128\/JVI.01621-12 .","journal-title":"J Virol"},{"key":"607_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03689-14","author":"A O\u2019Hearn","year":"2015","unstructured":"O\u2019Hearn A, Wang M, Cheng H, Lear-Rooney CM, Koning K, Rumschlag-Booms E, et al. Role of EXT1 and glycosaminoglycans in the early stage of filovirus entry. J Virol. 2015. doi: 10.1128\/JVI.03689-14 .","journal-title":"J Virol"},{"key":"607_CR17","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1128\/JVI.03116-13","volume":"88","author":"LA Silva","year":"2014","unstructured":"Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol. 2014;88:2385\u201397. doi: 10.1128\/JVI.03116-13 .","journal-title":"J Virol"},{"key":"607_CR18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.6091268","volume":"226","author":"H Mitsuya","year":"1984","unstructured":"Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science. 1984;226:172\u20134.","journal-title":"Science"},{"key":"607_CR19","doi-asserted-by":"crossref","first-page":"24349","DOI":"10.1016\/S0021-9258(19)51089-4","volume":"269","author":"N Yahi","year":"1994","unstructured":"Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J Biol Chem. 1994;269:24349\u201353.","journal-title":"J Biol Chem"},{"key":"607_CR20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/JVI.77.2.1281-1291.2003","volume":"77","author":"HC Aguilar","year":"2003","unstructured":"Aguilar HC, Anderson WF, Cannon PM. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. J Virol. 2003;77:1281\u201391.","journal-title":"J Virol"},{"key":"607_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/aid.1.1986.2.63","volume":"2","author":"HA Kessler","year":"1986","unstructured":"Kessler HA, Pottage JC, Trenholme GM, Benson CA, Levin S. Effects of suramin on in vitro HBsAg production by PLC\/PRF\/5 cells and hepatitis B virus DNA polymerase activity. AIDS Res. 1986;2:63\u201372.","journal-title":"AIDS Res"},{"key":"607_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1096-9071(199903)57:3<238::AID-JMV5>3.0.CO;2-G","volume":"57","author":"JA Garson","year":"1999","unstructured":"Garson JA, Lubach D, Passas J, Whitby K, Grant PR. Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J Med Virol. 1999;57:238\u201342.","journal-title":"J Med Virol"},{"key":"607_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bbrc.2014.09.113","volume":"453","author":"C Basavannacharya","year":"2014","unstructured":"Basavannacharya C, Vasudevan SG. Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format. Biochem Biophys Res Commun. 2014;453:539\u201344. doi: 10.1016\/j.bbrc.2014.09.113 .","journal-title":"Biochem Biophys Res Commun"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2013.12.008","volume":"103","author":"Y Wang","year":"2014","unstructured":"Wang Y, Qing J, Sun Y, Rao Z. Suramin inhibits EV71 infection. Antivir Res. 2014;103:1\u20136. doi: 10.1016\/j.antiviral.2013.12.008 .","journal-title":"Antivir Res"},{"key":"607_CR25","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1128\/AAC.03595-14","volume":"58","author":"M Ellenbecker","year":"2014","unstructured":"Ellenbecker M, Lanchy J-M, Lodmell JS. Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin. Antimicrob Agents Chemother. 2014;58:7405\u201315. doi: 10.1128\/AAC.03595-14 .","journal-title":"Antimicrob Agents Chemother"},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.antiviral.2015.06.013","volume":"121","author":"IC Albulescu","year":"2015","unstructured":"Albulescu IC, van Hoolwerff M, Wolters LA, Bottaro E, Nastruzzi C, Yang SC, et al. Suramin inhibits chikungunya virus replication through multiple mechanisms. Antivir Res. 2015;121:39\u201346. doi: 10.1016\/j.antiviral.2015.06.013 .","journal-title":"Antivir Res"},{"key":"607_CR27","doi-asserted-by":"publisher","first-page":"e0133511","DOI":"10.1371\/journal.pone.0133511","volume":"10","author":"Y-J Ho","year":"2015","unstructured":"Ho Y-J, Wang Y-M, Lu J-W, Wu T-Y, Lin L-I, Kuo S-C, et al. Suramin Inhibits Chikungunya Virus Entry and Transmission. PLoS One. 2015;10:e0133511. doi: 10.1371\/journal.pone.0133511 .","journal-title":"PLoS One"},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"11374","DOI":"10.1128\/JVI.01067-10","volume":"84","author":"C Goffinet","year":"2010","unstructured":"Goffinet C, Schmidt S, Kern C, Oberbremer L, Keppler OT. Endogenous CD317\/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J Virol. 2010;84:11374\u201384. doi: 10.1128\/JVI.01067-10 .","journal-title":"J Virol"},{"key":"607_CR29","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463\u201371.","journal-title":"J Virol"},{"key":"607_CR30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2006.03.025","volume":"14","author":"S Agarwal","year":"2006","unstructured":"Agarwal S, Nikolai B, Yamaguchi T, Lech P, Somia NV, N1 - Department of Genetics, Cell Biology, and Development, Institute of Human Genetics, University of Minnesota, 420 Delaware Street SE, MMC 206, Minneapolis, MN 55455, USAFAgarwal, Sumit. Construction and use of retroviral vectors encoding the toxic gene barnase. Mol Ther. 2006;14:555\u201363.","journal-title":"Mol Ther"},{"key":"607_CR31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/nar\/23.4.628","volume":"23","author":"Y Soneoka","year":"1995","unstructured":"Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23:628\u201333.","journal-title":"Nucleic Acids Res"},{"key":"607_CR32","doi-asserted-by":"publisher","unstructured":"Hierholzer JC, Killington RA. Virus isolation and quantitation. In: Virology Methods Manual: Elsevier; 1996. p. 25\u201346. doi: 10.1016\/B978-012465330-6\/50003-8 .","DOI":"10.1016\/B978-012465330-6\/50003-8"},{"key":"607_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.antiviral.2015.11.007","volume":"125","author":"C Rhein von","year":"2016","unstructured":"von Rhein C, Weidner T, Hen\u00df L, Martin J, Weber C, Sliva K, Schnierle BS. Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in vitro. Antivir Res. 2016;125:51\u20137. doi: 10.1016\/j.antiviral.2015.11.007 .","journal-title":"Antivir Res"},{"key":"607_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.001","volume":"113","author":"C Weber","year":"2015","unstructured":"Weber C, Sliva K, von Rhein C, K\u00fcmmerer BM, Schnierle BS. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antivir Res. 2015;113:1\u20133. doi: 10.1016\/j.antiviral.2014.11.001 .","journal-title":"Antivir Res"},{"key":"607_CR35","doi-asserted-by":"publisher","unstructured":"Cureton DK, Massol RH, Saffarian S, Kirchhausen TL, Whelan, Sean P J. Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog. 2009;5:e1000394. doi: 10.1371\/journal.ppat.1000394","DOI":"10.1371\/journal.ppat.1000394"},{"key":"607_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0166-3542(87)90034-9","volume":"7","author":"E Clercq de","year":"1987","unstructured":"de Clercq E. Suramin in the treatment of AIDS: Mechanism of action. Antiviral Res. 1987;7:1\u201310. doi: 10.1016\/0166-3542(87)90034-9 .","journal-title":"Antiviral Res"},{"key":"607_CR37","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/hep.21896","volume":"46","author":"A Schulze","year":"2007","unstructured":"Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007;46:1759\u201368. doi: 10.1002\/hep.21896 .","journal-title":"Hepatology"},{"key":"607_CR38","first-page":"187","volume":"3","author":"MA Eisenberger","year":"1995","unstructured":"Eisenberger MA, Sinibaldi V, Reyno L. Suramin. Cancer Pract. 1995;3:187\u20139.","journal-title":"Cancer Pract"},{"key":"607_CR39","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2174\/138955708786369573","volume":"8","author":"RP McGeary","year":"2008","unstructured":"McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008;8:1384\u201394.","journal-title":"Mini Rev Med Chem"},{"key":"607_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/clpt.1992.97","volume":"52","author":"MR Cooper","year":"1992","unstructured":"Cooper MR, Lieberman R, La Rocca RV, Renato V, Gernt PR, Weinberger MS, Headlee DJ, et al. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther. 1992;52:11\u201323. doi: 10.1038\/clpt.1992.97 .","journal-title":"Clin. Pharmacol. Ther"},{"key":"607_CR41","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S8372","volume":"5","author":"OE Babalola","year":"2011","unstructured":"Babalola OE. Ocular onchocerciasis: current management and future prospects. Clin Ophthalmol. 2011;5:1479\u201391. doi: 10.2147\/OPTH.S8372 .","journal-title":"Clin Ophthalmol"},{"key":"607_CR42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1989.7.4.499","volume":"7","author":"CA Stein","year":"1989","unstructured":"Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989;7:499\u2013508.","journal-title":"J Clin Oncol"},{"key":"607_CR43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0006-291X(86)90877-6","volume":"136","author":"J Balzarini","year":"1986","unstructured":"Balzarini J, Mitsuya H, de Clercq E, Broder S. Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III\/lymphadenopathy-associated virus. Biochem Biophys Res Commun. 1986;136:64\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"607_CR44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1054-3589(08)60486-X","volume":"15","author":"F Hawking","year":"1978","unstructured":"Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978;15:289\u2013322.","journal-title":"Adv Pharmacol Chemother"},{"key":"607_CR45","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJM198605293142216","volume":"314","author":"AB Weitberg","year":"1986","unstructured":"Weitberg AB, Mayer K, Miller ME, Mikolich DJ. Dysplastic carcinoid tumor and AIDS-related complex. N Engl J Med. 1986;314:1455. doi: 10.1056\/NEJM198605293142216 .","journal-title":"N Engl J Med"},{"key":"607_CR46","first-page":"273","volume":"71","author":"MK Horne 3rd","year":"1988","unstructured":"Horne 3rd MK, Stein CA, La Rocca RV, Myers CE. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood. 1988;71:273\u20139.","journal-title":"Blood"},{"key":"607_CR47","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1038\/emi.2014.88","volume":"3","author":"J Kouznetsova","year":"2014","unstructured":"Kouznetsova J, Sun W, Mart\u00ednez-Romero C, Tawa G, Shinn P, Chen CZ, et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3:e84. doi: 10.1038\/emi.2014.88 .","journal-title":"Emerg Microbes Infect"},{"key":"607_CR48","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/jac\/dku091","volume":"69","author":"G Gehring","year":"2014","unstructured":"Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69:2123\u201331. doi: 10.1093\/jac\/dku091 .","journal-title":"J Antimicrob Chemother"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-016-0607-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T16:57:28Z","timestamp":1657213048000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-016-0607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1186\/s12985-016-0607-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]},"article-number":"149"}}